The acquisition will enable the company to market and distribute a wide range of pharmaceuticals including generics, biosimilars, biologics and innovative pharmaceuticals products in Germany and Europe. Briefing reporters, Biocon Chairman & Managing Director Kiran Mazumdar-Shaw said, “AxiCorp is a key strategic investment for Biocon as it heralds our European foray for biosimilars like Recombinant Human Insulin.” With this acquisition, Biocon will be able to market its injectible insulin on its own, she added. AxiCorp is a specialised marketing and distribution company established in 2002 by a group of industry experts to address the lucrative generics and parallel distribution market in Germany and Europe.